Altasciences has the unique expertise and experience to successfully scale up R&D formulations for clinical manufacturing.

In this case study, you’ll learn how we optimized the milling conditions for the manufacturing process of a nanosuspended dosage form to ensure a sufficient quantity of product to support our client’s Phase III clinical trials.

Find out how we did it!

READ CASE STUDY

Have a drug product that requires formulation and manufacturing for your nonclinical and clinical trials?
Contact us to get started.

You may also be interested in the following:

• Webpage: Contract Manufacturing and Analytical Solutions
• Scientific Journal: Nanomilling for Better Solubility and Improved Bioavailability
• Webinar: The Development of Nanosuspension Formulations for Poorly Soluble Drugs

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.

Coupling Hybridization LC-MS Workflows with Microsampling for the Analysis of Antisense Oligonucleotides

Join Altasciences’ scientific experts as they discuss novel LC-MS-based strategies and workflows for the quantitative bioanalysis of oligonucleotide therapeutics (ASO) via dried blood microsampling.

Discover how this breakthrough novel application can:

• be applied to nonclinical studies
• facilitate remote sample collection for patient-centric trials
• eliminate the tedious and often error-prone approach that occurs when using liquid-based capillary microsampling

Speak with one of our experts to learn more about our service offering.

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services.

Have five minutes? Take a look at these:

• Webpages:
  • Microsampling Expertise
  • Bioanalytical Platforms
• Podcast: Microsampling: When Small Steps Lead to Big Outcomes
• eBook: Developments for the Analysis of Antisense Oligonucleotides
• The Altascientist: Microsampling in Drug Development
• Webinar: Patient Centricity and the Evolving Role of Microsampling

We are pleased to share with you three scientific posters that were presented by our nonclinical experts at the ACT 2022 Annual Meeting.

In Vivo and Histological Analysis of Focal Chorioretinal Defects in Dutch Belted Rabbits
This study analyzes the in vivo retinal microanatomy findings observed during pretest ophthalmic examination in laboratory rabbits. Listen or view the poster now.

Establishment of an Induced Hemophilia A Model in Anesthetized Cynomolgus Monkeys
Discover how to successfully establish an experimentally induced hemophilia A model in cynomolgus monkeys. Listen or view the poster now.

A Case Study Comparison of Traditional vs. Modified Methods for Surgical Closing and Post-Operative Treatment for Muscle Biopsy Sites in Nonhuman Primates
Learn how a modified method for surgical closing treatment in muscle biopsy sites in nonhuman primates can reduce post-operative complications, including dehiscence and infections. Listen or view the poster now.

Book a consult with one of our experts to discuss how we can support your program.

You might also be interested in:

• eBook: Preclinical Assessment Planning Guide
• Fact Sheet: Preclinical Drug Development Capabilities
• Webpage: Preclinical Solutions

Accelerate Your Clinical Trials with Liquid-Filled Capsules

Liquid-filled, two-piece capsules offer countless advantages over other solid dosage forms―ease of scalability and manufacturing, faster absorption, simpler packaging, and higher product stability, to name a few.

They are also the recommended dosage form for insoluble or highly potent APIs, and are known to accelerate product development because they can be made with fewer excipients than other solid dosage forms, such as tablets.

Discover the full benefits of using liquid-filled capsules in your clinical trials, or view this infographic for a quick tutorial.

Related Resources:

• Webpage: Contract Manufacturing and Analytical Solutions
• eBook: Applications of Liquid-Filled Capsules in Drug Development
• Webinar: Manufacturing Solutions Using Liquid-Filled Capsules

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.

Surrogate Cerebrospinal Fluid Method for ASO Quantitation

In this presentation, we identify a suitable surrogate matrix to overcome issues regarding the shortage of nonhuman primate matrices, and susceptibility to non-specific binding (inherent in the analysis of oligonucleotides), including the use of artificial cerebrospinal fluid.

Listen to the presentation!

You may also be interested in the following:

• Webpages:
  • Oligonucleotide Capabilities
  • Bioanalytical Platforms
• eBook: Bioanalytical Developments for the Analysis of ASOs​​​​​​

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services.

Listen to the Latest Scientific Audiobook Releases

Delve deeper into the critical processes behind early phase drug development with audio versions of eBooks and The Altascientist, written by our experts with you in mind:

The Altascientist: Issue 30 — The Evolution and Advancement of LCMS in Drug Development Learn how the latest LC-MS advancements ensure accurate and precise data delivery in your drug development program. Listen to the audiobook >>>	The Altascientist: Issue 28 — Applications of Liquid-Filled, Hard-Shell Capsules in Drug Development Discover the advantages that liquid-filled, hard-shell capsules offer for the formulation of highly potent APIs and drugs that benefit from slow or extended release. Listen to the audiobook >>>
The Altascientist: Issue 29 — Building Your Early Phase Clinical Trial Data, From Protocol to Regulatory Submission Explore best practices and approaches for mitigating challenges when it comes to your data and bringing your drug to market. Listen to the audiobook >>>	eBook: First-in-Human Solution for Small and Large Molecules Uncover Altasciences' comprehensive, multi-service solution for your first-in-human trials—beyond the clinic. Listen to the audiobook >>>

Conducting your early phase clinical research in Canada for novel compounds can provide significant advantages. Altasciences’ Canadian clinical pharmacology unit offers 25 years of experience, and can ensure you receive the quality data you need for faster, more informed go/no-go decisions.

Here’s how we support you in Canada:

• 265-bed with over 200 clinical trial experts
• Dedicated USP 797 certified pharmacy that can handle Schedule I classification
• 15-minute drive to our bioanalytical laboratory for small/large molecule analysis, PD biomarkers, and flow cytometry
• Proven recruitment with a database of over 50,000 active participants
• Access to special populations and patients for proof-of-concept (POC) arms
• Neuro/CNS specialization—human abuse potential (HAP), cognition, pain models, and CFS collections
• 10 on-site driving simulators with 13,000+ simulated drives conducted
• 14 Principal Investigators—four with GI, ophthalmology, and general practitioner background
• Access to specialty physicians for protocol-specific needs
• Strong relationship with Health Canada and over 120 submissions per year

Virtually step inside our Montréal facility: WATCH NOW

You may also be interested in the following:

• Webpages:
  • Our Three Clinical Trial Facilities
  • Clinical Research Services
• Video:
  • Quick Chat with Dr. Morelli

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services.